"bharat-biotech"

Hyderabad: Hyderabad-based Bharat Biotech said it will ramp up the manufacturing capacities for Covaxin, at Chiron Behring Vaccines, Ankleshwar Gujarat, a wholly owned subsidiary of Bharat Biotech. The company plans to produce 200 million (20 crore) doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based […]

Company plans to produce an additional 200 million doses of Covaxin per annum in the GMP facilities located at Ankleshwar, Gujarat, starting from the fourth quarter of 2021

The discussions are currently ongoing with Bharat Biotech towards reviewing the infrastructure at Hester, the technology adaption process and the regulatory compliances.

The Minister spoke about his personal isolation experience to the decision on imposing lockdown, vaccine for children to India seeking help from other countries, among other things

States may face delays in getting approvals from Indian drug regulatory authorities

States like Telangana opting for global tenders to procure vaccine is a pragmatic decision, given the Centre's opaque policy

The price factor will not have any impact on the ultimate beneficiary namely, the eligible person getting the vaccine since all state governments have already declared their policy decision.

To enhance vaccination penetration into corporate hubs and housing societies in Hyderabad, Bengaluru and Chennai

"Now, this is something we are still gaining data on, but most recent data looking at convalescent sera of Covid-19 cases in people who received Covaxin, it was found to neutralise the 617 variant," Fauci was quoted as saying during the White House press briefing

This message was conveyed to Chief Secretary Somesh Kumar who held a meeting with Dr. Krishna Ella, MD, Bharat Biotech on Tuesday at BRKR Bhavan following directions from Chief Minister K. Chandrashekar Rao.

Bharat Biotech CMD Krishna M Ella said the company is supplying the vaccine to the Central Government at Rs 150 per dosage

Safety and efficacy results from the final analysis will be available in June and the final report will be submitted to a peer-reviewed publication, says Bharat Biotech

The top research institute said that “NIV has also demonstrated the neutralisation potential of Covaxin against the UK and Brazil variants.”

Hyderabad-based vaccine maker implements expansion across multiple facilities in Hyderabad and Bengaluru to reach about 700 million doses per year capacity

"The agreement with Precisa Medicamentos is based on a long term partnership and will continue,” Bharat Biotech stated.

Soon after the outbreak, the industry quickly adapted to the supply chain needs and manpower scenario and got into making generic drugs and vaccine development.

According to the interim results of the phase 2 trials published in The Lancet Infectious Diseases journal.

The study showed that 54 per cent of the population in the city has antibodies, which means they have developed immunity to SARS-CoV-2 virus

The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with the Indian Council of Medical Research, the Hyderabad-based company said in a statement.

Both SII and Bharat Biotech are involved in producing Covid-19 vaccine